ReportGem ReportGem

U.S. COMPANY FILING

ALNYLAM PHARMACEUTICALS, INC. — Form 10-Q filed 2026-04-30

Filed: 2026-04-30Company: ALNYLAM PHARMACEUTICALS, INC.Ticker: ALNYExchange: NasdaqForm: 10-QReport period: 2026-03-31SEC accession: 0001628280-26-028605Event: earningsMateriality: 90

Filing text preview

Alnylam reported Q1 2026 total revenues of $1.17B, up 96% YoY, with net income of $206M, marking the first profitable quarter. AMVUTTRA US sales surged 255% to $703M. The company continues its Alnylam 2030 strategy but faces risks including reliance on AMVUTTRA and high-interest financing.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-04-3010-Q2026-07-30 · 10-Q8-K2026-07-30 · 8-K8-K2026-04-30 · 8-K10-K2026-02-12 · 10-K8-K2026-02-12 · 8-K8-K2026-01-12 · 8-K